Q1 cash $29.3M; closed $180M upfront financing; expects CRL by June 20, 2026; new CEO appointed

ACHIEVE LIFE SCIENCES, INC.

• Q1 cash, equivalents, and marketable securities $29.3M; net loss $10.2M, operating expenses $10.5M.
• Closed private placement of up to $354M ($180M upfront + $174M milestone warrants).
• Andrew D. Goldberg, MD appointed CEO and board member; Christopher Martin added as director.
• Expects CRL from FDA by June 20, 2026; to resubmit NDA in Q4 2026 with new manufacturer Adare.
• Jaime Xinos departs as CCO May 31; Lucian Iancovici becomes Chair; Tom King steps down June 8.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.